LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus
Victoria P. Werth(Philadelphia VA Medical Center), Shimon Korish(Bristol-Myers Squibb (United States)), Malavi T. Madireddi(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Joseph F. Merola(Southwestern Medical Center), Shalabh Singhal(Integrated BioTherapeutics (United States)), Richard Meier(Bristol-Myers Squibb (United States)), Joerg Wenzel(University of Bonn), Harini Kothari(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|379
239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018
|Neuromuscular Disorders|2019|308
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus
|Journal of Investigative Dermatology|2009|238